<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Henri G Colt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bronchoalveolar lavage (BAL) is a minimally invasive procedure performed during flexible bronchoscopy to obtain a sample of alveolar cells. Analysis of BAL cell counts, cytology, and culture provides insights into immunologic, inflammatory, neoplastic, and infectious processes occurring at the alveolar level.</p><p>This topic will review the role of BAL in the setting of interstitial lung disease (ILD) and the cell profiles found in common interstitial lung diseases [<a href="#rid1">1,2</a>]. The technique of BAL and the analysis of lavage fluid are discussed separately, as is the overall approach to the patient with ILD.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CONSTITUENTS OF BAL IN ILD</span><span class="headingEndMark"> — </span>In the evaluation of interstitial lung disease (ILD), bronchoalveolar lavage (BAL) findings are typically consistent with or suggestive of a given condition, rather than pathognomonic [<a href="#rid3">3,4</a>]. In patients with an acute presentation of dyspnea and interstitial opacities, BAL is sometimes helpful to identify alveolar hemorrhage, eosinophilia, malignancy, or opportunistic infection  (<a class="graphic graphic_table graphicRef55231" href="/z/d/graphic/55231.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p>When BAL fluid is obtained from healthy adults, only small numbers of lymphocytes, neutrophils, and eosinophils accompany the predominant population of alveolar macrophages  (<a class="graphic graphic_table graphicRef50382 graphicRef71367 graphicRef66165" href="/z/d/graphic/50382.html" rel="external">table 2A-C</a>) [<a href="#rid5">5,6</a>]. In patients with interstitial lung disease (ILD), a variety of changes in the relative and absolute numbers of individual cell constituents have been described. Usually, these changes are nonspecific, but occasionally, the pattern is sufficiently characteristic to guide the differential diagnosis  (<a class="graphic graphic_table graphicRef54377" href="/z/d/graphic/54377.html" rel="external">table 3</a>), or rarely, to confirm the diagnosis of a particular ILD  (<a class="graphic graphic_table graphicRef55231" href="/z/d/graphic/55231.html" rel="external">table 1</a>) [<a href="#rid1">1,7-11</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytosis (usually greater than 30 percent of the total white cells)  (<a class="graphic graphic_table graphicRef69908" href="/z/d/graphic/69908.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ratio of CD4 positive to CD8 positive lymphocytes (CD4/CD8) may permit further narrowing of the possible diagnoses  (<a class="graphic graphic_table graphicRef63294" href="/z/d/graphic/63294.html" rel="external">table 5</a>) [<a href="#rid7">7,12</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eosinophilic (usually greater than 5 percent of the white cells)  (<a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 6</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant cells (eg, metastatic carcinoma, Reed-Sternberg cells, monoclonal B lymphocytes)  (<a class="graphic graphic_table graphicRef55231" href="/z/d/graphic/55231.html" rel="external">table 1</a>)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">LYMPHOCYTIC BAL</span><span class="headingEndMark"> — </span>The classic diseases associated with a lymphocytic BAL are hypersensitivity pneumonitis (HP), sarcoidosis, and cryptogenic organizing pneumonia. Other diseases, such as idiopathic pulmonary fibrosis (IPF), non-IPF idiopathic interstitial pneumonias, connective tissue disease-associated interstitial lung disease, and berylliosis are associated with increased BAL lymphocyte counts, although generally at lower levels than HP or sarcoidosis  (<a class="graphic graphic_table graphicRef69908" href="/z/d/graphic/69908.html" rel="external">table 4</a>). </p><p class="headingAnchor" id="H4"><span class="h2">Hypersensitivity pneumonitis</span><span class="headingEndMark"> — </span>Bronchoalveolar lavage (BAL), especially when combined with transbronchial biopsy, is a sensitive tool for detecting an alveolitis in patients suspected of hypersensitivity pneumonitis (HP) [<a href="#rid13">13</a>]. A marked lymphocytosis (often exceeding 50 percent of the cells recovered) is a nonspecific but helpful finding, since this level of lymphocytosis is uncommon in diseases often considered in the differential diagnosis. The CD4/CD8 ratio may be decreased (&lt;1), but this is not useful diagnostically [<a href="#rid2">2,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'Bronchoalveolar lavage'</a>.)</p><p>A systematic review found that a BAL cell count ≥20 percent lymphocytes distinguished fibrotic HP from IPF with a sensitivity and specificity of 69 and 61 percent, respectively, and distinguished nonfibrotic HP from IPF with a sensitivity and specificity of 95 and 61 percent, respectively [<a href="#rid14">14</a>]. Similar percentages were noted in a separate systematic review [<a href="#rid15">15</a>]. However, it was not possible to determine an exact threshold that could be used to separate HP and IPF with high sensitivity and high specificity. Different causes and stages of HP, and also differences in specimen acquisition and processing, contribute to variations in lymphocyte percentages [<a href="#rid16">16</a>]. </p><p>Among patients with chronic HP, older age and current or prior cigarette smoking are associated with lower lymphocyte percentages [<a href="#rid15">15</a>]. An increased number of mast cells (&gt;1 percent) may be noted in HP, although this is not generally used clinically. The presence of mast cells may also be helpful in monitoring for ongoing exposure to the responsible antigen, as mast cells are usually increased following acute exposure and decline toward normal within one to three months after removal of exposure [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Sarcoidosis</span><span class="headingEndMark"> — </span>The diagnosis of sarcoidosis cannot be established on the basis of BAL findings alone. However, certain patterns on BAL can help to narrow the differential diagnosis. Criteria for the diagnosis of sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p>In the majority of patients with sarcoidosis, the BAL lymphocyte count and percentage are increased, while the neutrophil and eosinophil percentages are normal  (<a class="graphic graphic_table graphicRef54377" href="/z/d/graphic/54377.html" rel="external">table 3</a>) [<a href="#rid12">12,18,19</a>]. In addition, a predominance of T-lymphocytes with an elevated CD4/CD8 ratio is a frequent finding, although not sufficient for diagnosis  (<a class="graphic graphic_table graphicRef63294" href="/z/d/graphic/63294.html" rel="external">table 5</a>) [<a href="#rid7">7,18,20,21</a>]. The duration of disease and the clinical variables (eg, the presence of extrapulmonary disease) appear to affect the cellular patterns in the recovered fluid, as follows [<a href="#rid22">22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"Early" or active sarcoidosis is characterized by increases in the total numbers of cells recovered, the number of lymphocytes ("high intensity alveolitis"), and the CD4/CD8 T-lymphocyte ratio (&gt;2:1) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Late" or advanced sarcoidosis is characterized by a relative increase in CD8 T-lymphocytes and neutrophils (to greater than 3 percent of the total). Significant numbers of mast cells in BAL fluid (&gt;1 percent), particularly in combination with BAL lymphocytosis or neutrophilia, are associated with advanced or progressive sarcoidosis [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single BAL that shows a normal CD4/CD8 T-lymphocyte ratio may predict a good prognosis [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial lavage analysis may be more helpful in defining the disease course than a single BAL analysis early in the course of the disease, although it does not add substantially to the information obtained from serial pulmonary function tests. In the subset of patients with persistent BAL lymphocytosis and/or a persistently elevated CD4/CD8 T-lymphocyte ratio, declines in lung function are more likely, particularly in untreated patients [<a href="#rid23">23-28</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h1">MIXED CELLULARITY BAL</span><span class="headingEndMark"> — </span>In a number of interstitial lung diseases, more than one type of cell may be increased in the bronchoalveolar lavage (BAL), or the proportions may vary over the course of the disease  (<a class="graphic graphic_table graphicRef54377" href="/z/d/graphic/54377.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef69908" href="/z/d/graphic/69908.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef76619" href="/z/d/graphic/76619.html" rel="external">table 7</a>). For these interstitial lung diseases (ILDs), even when a particular pattern is more common, the BAL results are not diagnostic.</p><p class="headingAnchor" id="H7"><span class="h2">Idiopathic pulmonary fibrosis</span><span class="headingEndMark"> — </span>Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance of usual interstitial pneumonia (UIP). BAL has a limited role in the diagnosis and management of IPF when the clinical impression is IPF and the high resolution computed tomography (HRCT) pattern is UIP [<a href="#rid29">29</a>]. On the other hand, cellular analysis of BAL can be useful to exclude other processes (eg, eosinophilic pneumonia, sarcoidosis, or infection) when the clinical impression suggests IPF, but the HRCT pattern is not clearly UIP. A definitive diagnosis of IPF in such patients usually requires lung biopsy. (See  <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">"Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"</a>.)</p><p>In patients with IPF, BAL cell counts usually show a several-fold increase in the total number of inflammatory cells [<a href="#rid30">30-36</a>]. However, the percentages of various cell types found in the lavage fluid do not correlate with clinical parameters, or pulmonary function studies. Nevertheless, some cell count patterns have been noted and may be helpful. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with suspected IPF, a BAL lymphocyte count less than 30 percent is consistent with IPF, whereas a higher percentage may suggest an alternate diagnosis. As an example, among 74 patients with IPF suggested by the clinical presentation and HRCT scanning, the only patients who were determined to have a non-IPF diagnosis (eg, hypersensitivity pneumonitis, nonspecific interstitial pneumonia) had a BAL lymphocytosis of 30 percent or greater [<a href="#rid12">12</a>]. (See <a class="local">'Hypersensitivity pneumonitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conflicting results have been reported regarding the significance of BAL neutrophilia in IPF [<a href="#rid37">37-39</a>]. In the largest series of 156 patients with biopsy proven IPF, each doubling of baseline BAL fluid neutrophil percentage was associated with a 30 percent increase in risk of mortality [<a href="#rid39">39</a>]. In a separate study of 81 IPF patients, BAL fluid neutrophil and lymphocyte counts predicted mortality in current smokers, but not among never smokers or former smokers in an adjusted analysis [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased BAL fluid lymphocyte and eosinophil percentages have been variably associated with increased mortality [<a href="#rid38">38,39</a>].</p><p></p><p>The role of BAL in the assessment of the cause of acute exacerbations of IPF is not clear and has not been found to be useful in excluding infection [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">"Acute exacerbations of idiopathic pulmonary fibrosis", section on 'Flexible bronchoscopy'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Nonspecific interstitial pneumonia</span><span class="headingEndMark"> — </span>Several case series have noted a lymphocytic BAL in patients with nonspecific interstitial pneumonia (NSIP), although others have not found this. It is possible that this reflects varying proportions of patients with cellular versus fibrotic NSIP. In a study that compared BAL cell counts from 35 patients with IPF and 19 with fibrotic NSIP, no significant difference was noted in the numbers or relative proportions of cells [<a href="#rid37">37</a>]. </p><p>A study that measured calgranulin B (small calcium-binding protein mainly involved in chronic inflammation, particularly neutrophil activity) and Krebs von den Lungen 6 (KL-6) in BAL fluid of patients with IPF and idiopathic NSIP (i-NSIP) with fibrotic pattern suggests that these proteins may prove to be reliable biomarkers of IPF and i-NSIP and to discriminate severe and advanced patients [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Cryptogenic organizing pneumonia</span><span class="headingEndMark"> — </span>The consistent, though nonspecific, BAL findings in cryptogenic organizing pneumonitis (COP) include an increased total number of cells and often a "mixed pattern" characterized by increases in the total number of macrophages, lymphocytes, neutrophils, and eosinophils. The CD4/CD8 ratio is usually decreased. These findings are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Invasive testing to rule out alternative diagnoses'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Connective tissue diseases</span><span class="headingEndMark"> — </span>BAL appears to have a limited value in the diagnosis, assessment, and monitoring of connective tissue diseases affecting the lung [<a href="#rid7">7,42</a>]. However, BAL may be valuable in clarifying other pulmonary problems which may develop in this setting, including drug-induced pulmonary disease, infection, pulmonary hemorrhage, alveolar proteinosis, and malignancy.</p><p>The typical BAL cell counts reported in various connective tissue diseases with and without concomitant ILD are shown in the table  (<a class="graphic graphic_table graphicRef73147" href="/z/d/graphic/73147.html" rel="external">table 8</a>). These findings are discussed further under the individual topic reviews. (See  <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">"Interstitial lung disease in rheumatoid arthritis", section on 'Bronchoalveolar lavage'</a> and  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Bronchoalveolar lavage'</a> and  <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Bronchoalveolar lavage'</a> and  <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">"Lymphoid interstitial pneumonia", section on 'Bronchoalveolar lavage'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Drug-induced pulmonary disease</span><span class="headingEndMark"> — </span>Many drugs have been associated with interstitial lung disease. Examples include <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, chemotherapeutic agents, and cocaine (see appropriate topic reviews). Often the diagnosis is not suspected or is difficult to confirm. BAL may be of value in suggesting the presence of drug-related lung injury, or in ruling out other problems (eg, infection or recurrent malignancy) that are common when chemotherapeutic agents are used [<a href="#rid43">43</a>]. The patterns of BAL findings suggestive of drug-related lung disease are shown in the table  (<a class="graphic graphic_table graphicRef52198" href="/z/d/graphic/52198.html" rel="external">table 9</a>). (See  <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment", section on 'Bronchoscopy and bronchoalveolar lavage'</a> and  <a class="medical medical_review" href="/z/d/html/4371.html" rel="external">"Nitrofurantoin-induced pulmonary injury", section on 'Bronchoalveolar lavage'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">EOSINOPHILIC BAL</span><span class="headingEndMark"> — </span>A marked increase in the bronchoalveolar lavage (BAL) eosinophil count (≥30 percent) is typically a manifestation of idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia (CEP), or tropical pulmonary eosinophilia. More modest increases in BAL eosinophils (&lt;30 percent) may be seen in idiopathic pulmonary fibrosis (IPF), sarcoidosis, pulmonary Langerhans cell histiocytosis, drug-induced pneumonitis, coccidioidal infection, and connective tissue diseases affecting the lungs  (<a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Acute eosinophilic pneumonia</span><span class="headingEndMark"> — </span>Idiopathic acute eosinophilic pneumonia is an acute febrile pneumonitis of less than one week duration with marked eosinophil accumulation in the lungs. At the onset, the chest radiograph may show only subtle reticular or hazy opacities, often with Kerley B lines. However, most patients present with or develop diffuse, mixed alveolar and reticular opacities. BAL eosinophil counts are typically over 25 percent. The differential diagnosis includes drug-induced pneumonitis, tropical pulmonary eosinophilia, fungal infection, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss). (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Chronic eosinophilic pneumonia</span><span class="headingEndMark"> — </span>Chronic eosinophilic pneumonia (CEP) is a disorder characterized by an indolent onset of dyspnea and a chest radiograph with bilateral peripheral opacities described as the "photographic negative" of pulmonary edema. In a patient with a compatible clinical presentation, a BAL eosinophil count greater than 40 percent is strongly suggestive of CEP. (See  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia", section on 'Chronic eosinophilic pneumonia'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Eosinophilia and infection</span><span class="headingEndMark"> — </span>BAL eosinophilia may also be seen in patients with <em>Coccidioidomycosis</em> infection and tropical filarial pulmonary eosinophilia [<a href="#rid44">44,45</a>]. The presentation and diagnosis of these diseases are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a> and  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">HEMORRHAGIC BAL</span><span class="headingEndMark"> — </span>Diffuse pulmonary hemorrhage occurs in a variety of conditions and is frequently a life-threatening event [<a href="#rid46">46</a>]. Patients usually report dyspnea, but hemoptysis is variable. The chest radiograph usually shows new patchy or diffuse alveolar opacities, although recurrent episodes may result in interstitial opacities. Frankly bloody or blood-tinged bronchoalveolar lavage (BAL) fluid suggests this diagnosis, particularly when the amount of blood in the effluent increases over three successive lavages. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes", section on 'Bronchoalveolar lavage'</a>.)</p><p>Additional cytologic findings include the demonstration of hemophagocytosis by alveolar macrophages or the presence of hemosiderin-laden macrophages [<a href="#rid7">7,47-54</a>].   </p><p>Once the diagnosis of pulmonary hemorrhage is confirmed, then the specific cause of the process must be sought [<a href="#rid48">48,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">OTHER USEFUL BAL FINDINGS</span><span class="headingEndMark"> — </span>In addition to changes in the number and proportion of cells, other findings in the bronchoalveolar lavage (BAL) may be helpful. Some of these are described below and include the presence of lipid-laden macrophages, malignant cells, mineral dust, and an increase in the number of CD1 positive Langerhans cells. The presence of alveolar macrophages with large, lamellated inclusion bodies is consistent with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> use, but not necessarily indicative of amiodarone toxicity  (<a class="graphic graphic_table graphicRef52198" href="/z/d/graphic/52198.html" rel="external">table 9</a>). (See <a class="local">'Drug-induced pulmonary disease'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h2">Chronic microaspiration</span><span class="headingEndMark"> — </span>Gastroesophageal reflux with aspiration is frequently considered in the differential diagnosis of recurrent pneumonia or atypical, diffuse interstitial opacities. When chronic aspiration is suspected, BAL should be performed in the area of greatest radiographic abnormality (usually the dependent lung zones).</p><p>BAL cellularity is increased and the differential reveals increases in lymphocytes, eosinophils, and macrophages. The most important diagnostic finding is the presence of large numbers of lipid-laden macrophages, which is suggestive of chronic aspiration or lipoid pneumonia [<a href="#rid55">55</a>]. Marked vacuolization of the alveolar macrophages is appreciated on routine modified Wright's staining; fat staining with oil-red-O or Sudan black demonstrates the lipid nature of the vacuoles [<a href="#rid55">55</a>]. Multinucleated giant cells may be recovered by BAL and frequently contain lipid droplets within their cytoplasm [<a href="#rid56">56-59</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Malignant cells</span><span class="headingEndMark"> — </span>Malignancies such as lymphangitic carcinomatosis and pulmonary lymphoma can sometimes present with diffuse interstitial opacities and be diagnosed by BAL [<a href="#rid60">60</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of patients with lymphangitic breast cancer, the BAL cytology revealed metastatic tumor in 10 of the 14 [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reed-Sternberg cells were identified in the BAL from 6 of 50 patients [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with primary pulmonary lymphoma, lymphocytic alveolitis (&gt;20 percent lymphocytes) is suggestive. Flow cytometry of BAL fluid can then be used to identify a clonal B-cell population with Ig gene clonal rearrangements [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Pneumoconioses</span><span class="headingEndMark"> — </span>The diagnosis of occupational lung disease rarely requires tissue biopsy or BAL. However, BAL can sometimes demonstrate respiratory tract deposition and retention of mineral dusts. The amount of mineral dust recovered appears to bear some relationship to the severity of the exposure, but considerable overlap occurs among asymptomatic, exposed workers and those with clinical disease (see  <a class="medical medical_review" href="/z/d/html/4307.html" rel="external">"Asbestos-related pleuropulmonary disease"</a>). Thus, BAL findings in individual patients must be considered with caution.</p><p>The potential usefulness of antigen-specific lymphocyte transformation tests (eg, beryllium) in the diagnosis of specific occupational lung diseases is under investigation. The beryllium lymphocyte proliferation test performed on peripheral blood or BAL fluid has become the standard industry surveillance tool for identifying beryllium-exposed workers who are beryllium-sensitized or in the early stages of chronic beryllium disease. (See  <a class="medical medical_review" href="/z/d/html/4367.html" rel="external">"Chronic beryllium disease (berylliosis)"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Pulmonary Langerhans cell histiocytosis</span><span class="headingEndMark"> — </span>The characteristic finding in BAL from patients with pulmonary Langerhans cell histiocytosis is an increase in CD1 positive Langerhans cells to greater than 5 percent of total cells [<a href="#rid49">49,63</a>]. However, this finding has a low sensitivity and is only found in half of patients. The diagnostic yield of BAL is improved when the findings are combined with those of transbronchial biopsy [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis", section on 'Flexible bronchoscopy'</a>.)</p><p class="headingAnchor" id="H25806411"><span class="h2">Pulmonary alveolar proteinosis</span><span class="headingEndMark"> — </span>BAL samples from patients with pulmonary alveolar proteinosis typically have an opaque or milky appearance due to abundant flocculent lipoproteinaceous material, which may settle upon standing [<a href="#rid2">2</a>]. In addition, cytologic examination shows engorgement a background of amorphous, periodic acid-Schiff (PAS) positive material  (<a class="graphic graphic_picture graphicRef78010" href="/z/d/graphic/78010.html" rel="external">picture 1</a>) and engorgement of alveolar macrophages with PAS-positive material [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H932400821"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Bronchoalveolar lavage (BAL) is a minimally invasive procedure performed during flexible bronchoscopy to obtain a sample of alveolar cells. Changes in the relative and absolute numbers of cells in BAL fluid have been described in a variety of interstitial lung diseases (ILD). Usually, these changes are nonspecific, but occasionally they are sufficiently characteristic to narrow the differential diagnosis  (<a class="graphic graphic_table graphicRef54377" href="/z/d/graphic/54377.html" rel="external">table 3</a>). (See <a class="local">'Constituents of BAL in ILD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytic BAL </strong>– The classic diseases associated with a lymphocytic BAL are hypersensitivity pneumonitis (HP), sarcoidosis, and cryptogenic organizing pneumonia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In sarcoidosis lung disease, the BAL lymphocyte count and percentage are increased, while the neutrophil and eosinophil percentages are normal  (<a class="graphic graphic_table graphicRef54377" href="/z/d/graphic/54377.html" rel="external">table 3</a>). The CD4/CD8 T-lymphocyte ratio (&gt;2) is typically increased in early, active disease, but may be lower in more advanced disease. (See <a class="local">'Sarcoidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In hypersensitivity pneumonitis, BAL typically shows a marked lymphocytosis (often exceeding 50 percent of the cells recovered), which is uncommon in diseases often considered in the differential diagnosis. The CD4/CD8 ratio is usually decreased (&lt;1). (See <a class="local">'Hypersensitivity pneumonitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed cellularity BAL</strong> – A number of ILDs have nonspecific and variable increases in the BAL cell constituents, including idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, connective tissue disease-related ILD, and drug-induced ILD. In these diseases, the role of BAL is largely to exclude other processes. (See <a class="local">'Mixed cellularity BAL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BAL eosinophilia</strong> – The main causes of BAL eosinophilia (&gt;25 percent eosinophils) are idiopathic acute eosinophilic pneumonia, chronic eosinophilic pneumonia, and infection (eg, fungal and parasitic)  (<a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 6</a>). (See <a class="local">'Eosinophilic BAL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other identifying BAL characteristics</strong> – In patients with ILD and a compatible clinical presentation, BAL fluid should be examined for the presence of hemosiderin or lipid-laden macrophages, Langerhans cells, amorphous extracellular periodic acid-Schiff positive material and malignant cells that would indicate alveolar hemorrhage, lipoid pneumonia, pulmonary Langerhans histiocytosis, pulmonary alveolar proteinosis, or neoplastic disease, respectively  (<a class="graphic graphic_table graphicRef55231" href="/z/d/graphic/55231.html" rel="external">table 1</a>). (See <a class="local">'Other useful BAL findings'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kilinç G, Kolsuk EA. The role of bronchoalveolar lavage in diffuse parenchymal lung diseases. Curr Opin Pulm Med 2005; 11:417.</a></li><li><a class="nounderline abstract_t">Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185:1004.</a></li><li><a class="nounderline abstract_t">Singh K, Khan S, Agarwal S, et al. The performance of high-volume bronchoalveolar lavage for the evaluation and diagnosis of interstitial lung disease. Ann Thorac Surg 2014; 97:720.</a></li><li><a class="nounderline abstract_t">Lee W, Chung WS, Hong KS, Huh J. Clinical usefulness of bronchoalveolar lavage cellular analysis and lymphocyte subsets in diffuse interstitial lung diseases. Ann Lab Med 2015; 35:220.</a></li><li><a class="nounderline abstract_t">Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141:S169.</a></li><li><a class="nounderline abstract_t">Frye BC, Schupp JC, Rothe ME, et al. The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals. J Intern Med 2020; 287:54.</a></li><li><a class="nounderline abstract_t">Welker L, Jörres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004; 24:1000.</a></li><li><a class="nounderline abstract_t">Meyer KC. The role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med 2004; 25:637.</a></li><li><a class="nounderline abstract_t">Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.</a></li><li><a class="nounderline abstract_t">Capelozzi VL, Faludi EP, Balthazar AB, et al. Bronchoalveolar lavage improves diagnostic accuracy in patients with diffuse lung disease. Diagn Cytopathol 2013; 41:1.</a></li><li><a class="nounderline abstract_t">Bergantini L, d'Alessandro M, Cameli P, et al. Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases. Eur J Intern Med 2021; 89:76.</a></li><li><a class="nounderline abstract_t">Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:1043.</a></li><li><a class="nounderline abstract_t">Lynch DA, Rose CS, Way D, King TE Jr. Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study. AJR Am J Roentgenol 1992; 159:469.</a></li><li><a class="nounderline abstract_t">Patolia S, Tamae Kakazu M, Chami HA, et al. Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. Ann Am Thorac Soc 2020; 17:1455.</a></li><li><a class="nounderline abstract_t">Adderley N, Humphreys CJ, Barnes H, et al. Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis. Eur Respir J 2020; 56.</a></li><li><a class="nounderline abstract_t">Ryerson CJ. Making Sense of Bronchoalveolar Lavage Lymphocytosis in Fibrotic Interstitial Lung Disease. Ann Am Thorac Soc 2020; 17:1382.</a></li><li><a class="nounderline abstract_t">Semenzato G, Bjermer L, Costabel U, et al. Clinical guidelines and indications for bronchoalveolar lavage (BAL): extrinsic allergic alveolitis. Eur Respir J 1990; 3:945.</a></li><li><a class="nounderline abstract_t">Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med 2007; 28:486.</a></li><li><a class="nounderline abstract_t">Novosadova E, Navratilova Z, Ordeltova M, et al. Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases. J Thorac Dis 2019; 11:2287.</a></li><li><a class="nounderline abstract_t">Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352.</a></li><li><a class="nounderline abstract_t">Danila E, Norkūniene J, Jurgauskiene L, Malickaite R. Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J 2009; 3:214.</a></li><li><a class="nounderline abstract_t">Poulter LW, Rossi GA, Bjermer L, et al. The value of bronchoalveolar lavage in the diagnosis and prognosis of sarcoidosis. Eur Respir J 1990; 3:943.</a></li><li><a class="nounderline abstract_t">Costabel U, Bross KJ, Guzman J, et al. Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:418.</a></li><li><a class="nounderline abstract_t">Verstraeten A, Demedts M, Verwilghen J, et al. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 1990; 98:560.</a></li><li><a class="nounderline abstract_t">Bjermer L, Rosenhall L, Angström T, Hällgren R. Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis. Thorax 1988; 43:284.</a></li><li><a class="nounderline abstract_t">Okada M, Takahashi H, Nukiwa T, et al. Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis. Jpn J Med 1987; 26:360.</a></li><li><a class="nounderline abstract_t">Israel-Biet D, Venet A, Chrétien J. Persistent high alveolar lymphocytosis as a predictive criterion of chronic pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:395.</a></li><li><a class="nounderline abstract_t">Ceuppens JL, Lacquet LM, Mariën G, et al. Alveolar T-cell subsets in pulmonary sarcoidosis. Correlation with disease activity and effect of steroid treatment. Am Rev Respir Dis 1984; 129:563.</a></li><li><a class="nounderline abstract_t">Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198:e44.</a></li><li><a class="nounderline abstract_t">Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135:696.</a></li><li><a class="nounderline abstract_t">Haslam PL, Turton CW, Heard B, et al. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35:9.</a></li><li><a class="nounderline abstract_t">Haslam PL, Turton CW, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328.</a></li><li><a class="nounderline abstract_t">Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135:26.</a></li><li><a class="nounderline abstract_t">Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124:1.</a></li><li><a class="nounderline abstract_t">Merrill WW, Reynolds HY. Bronchial lavage in inflammatory lung disease. Clin Chest Med 1983; 4:71.</a></li><li><a class="nounderline abstract_t">Fireman E, Vardinon N, Burke M, et al. Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur Respir J 1998; 11:706.</a></li><li><a class="nounderline abstract_t">Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22:239.</a></li><li><a class="nounderline abstract_t">Tabuena RP, Nagai S, Tsutsumi T, et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients. Respiration 2005; 72:490.</a></li><li><a class="nounderline abstract_t">Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133:226.</a></li><li><a class="nounderline abstract_t">Petrosyan F, Culver DA, Reddy AJ. Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med 2015; 15:70.</a></li><li><a class="nounderline abstract_t">Bennett D, Salvini M, Fui A, et al. Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation 2019; 42:463.</a></li><li><a class="nounderline abstract_t">Wallaert B, Rossi GA, Sibille Y. Clinical guidelines and indications for bronchoalveolar lavage (BAL): collagen-vascular diseases. Eur Respir J 1990; 3:942.</a></li><li><a class="nounderline abstract_t">Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25:25.</a></li><li><a class="nounderline abstract_t">Swartz J, Stoller JK. Acute eosinophilic pneumonia complicating Coccidioides immitis pneumonia: a case report and literature review. Respiration 2009; 77:102.</a></li><li><a class="nounderline abstract_t">Ong RK, Doyle RL. Tropical pulmonary eosinophilia. Chest 1998; 113:1673.</a></li><li><a class="nounderline abstract_t">Lichtenberger JP 3rd, Digumarthy SR, Abbott GF, et al. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol 2014; 43:128.</a></li><li><a class="nounderline abstract_t">Kindt GC, Weiland JE, Davis WB, et al. Bronchiolitis in adults. A reversible cause of airway obstruction associated with airway neutrophils and neutrophil products. Am Rev Respir Dis 1989; 140:483.</a></li><li><a class="nounderline abstract_t">Grebski E, Hess T, Hold G, et al. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest 1992; 102:1794.</a></li><li><a class="nounderline abstract_t">Costabel U, Guzman J, Bonella F, Oshimo S. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med 2007; 28:514.</a></li><li><a class="nounderline abstract_t">Sherman JM, Winnie G, Thomassen MJ, et al. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest 1984; 86:409.</a></li><li><a class="nounderline abstract_t">Golde DW, Drew WL, Klein HZ, et al. Occult pulmonary haemorrhage in leukaemia. Br Med J 1975; 2:166.</a></li><li><a class="nounderline abstract_t">Drew WL, Finley TN, Golde DW. Diagnostic lavage and occult pulmonary hemorrhage in thrombocytopenic immunocompromised patients. Am Rev Respir Dis 1977; 116:215.</a></li><li><a class="nounderline abstract_t">Kahn FW, Jones JM, England DM. Diagnosis of pulmonary hemorrhage in the immunocompromised host. Am Rev Respir Dis 1987; 136:155.</a></li><li><a class="nounderline abstract_t">Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001; 7:255.</a></li><li><a class="nounderline abstract_t">Corwin RW, Irwin RS. The lipid-laden alveolar macrophage as a marker of aspiration in parenchymal lung disease. Am Rev Respir Dis 1985; 132:576.</a></li><li><a class="nounderline abstract_t">Lauque D, Dongay G, Levade T, et al. Bronchoalveolar lavage in liquid paraffin pneumonitis. Chest 1990; 98:1149.</a></li><li><a class="nounderline abstract_t">Silverman JF, Turner RC, West RL, Dillard TA. Bronchoalveolar lavage in the diagnosis of lipoid pneumonia. Diagn Cytopathol 1989; 5:3.</a></li><li><a class="nounderline abstract_t">Spatafora M, Bellia V, Ferrara G, Genova G. Diagnosis of a case of lipoid pneumonia by bronchoalveolar lavage. Respiration 1987; 52:154.</a></li><li><a class="nounderline abstract_t">Pujol JL, Barnéon G, Bousquet J, et al. Interstitial pulmonary disease induced by occupational exposure to paraffin. Chest 1990; 97:234.</a></li><li><a class="nounderline abstract_t">Rennard SI. Bronchoalveolar lavage in the diagnosis of cancer. Lung 1990; 168 Suppl:1035.</a></li><li><a class="nounderline abstract_t">Lower EE, Baughman RP. Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis. Chest 1992; 102:1113.</a></li><li><a class="nounderline abstract_t">Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20:750.</a></li><li><a class="nounderline abstract_t">Takizawa Y, Taniuchi N, Ghazizadeh M, et al. Bronchoalveolar lavage fluid analysis provides diagnostic information on pulmonary Langerhans cell histiocytosis. J Nippon Med Sch 2009; 76:84.</a></li><li><a class="nounderline abstract_t">Baqir M, Vassallo R, Maldonado F, et al. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013; 20:309.</a></li><li><a class="nounderline abstract_t">Chou CW, Lin FC, Tung SM, et al. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161:562.</a></li></ol></div><div id="topicVersionRevision">Topic 4308 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093816" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of bronchoalveolar lavage in diffuse parenchymal lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550210" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24484827" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The performance of high-volume bronchoalveolar lavage for the evaluation and diagnosis of interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25729724" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical usefulness of bronchoalveolar lavage cellular analysis and lymphocyte subsets in diffuse interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2186681" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612575" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572545" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564013" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of bronchoalveolar lavage in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674814" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bronchoalveolar lavage improves diagnostic accuracy in patients with diffuse lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33931268" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246718" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503007" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757946" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32265306" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33124908" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Making Sense of Bronchoalveolar Lavage Lymphocytosis in Fibrotic Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292296" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical guidelines and indications for bronchoalveolar lavage (BAL): extrinsic allergic alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975776" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bronchoalveolar lavage in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31372265" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339618" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20298407" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292295" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The value of bronchoalveolar lavage in the diagnosis and prognosis of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2942077" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394136" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3406915" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2826860" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3460384" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Persistent high alveolar lymphocytosis as a predictive criterion of chronic pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6231871" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alveolar T-cell subsets in pulmonary sarcoidosis. Correlation with disease activity and effect of steroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168753" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826895" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7361291" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7434282" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800151" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7258815" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6404585" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bronchial lavage in inflammatory lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596125" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952254" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210888" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071016" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160310" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30680696" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292294" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical guidelines and indications for bronchoalveolar lavage (BAL): collagen-vascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062594" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bronchoalveolar lavage in drug-induced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940333" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute eosinophilic pneumonia complicating Coccidioides immitis pneumonia: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631810" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tropical pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24791616" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diffuse pulmonary hemorrhage: clues to the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2548426" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bronchiolitis in adults. A reversible cause of airway obstruction associated with airway neutrophils and neutrophil products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446490" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975779" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bronchoalveolar lavage in other interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6468000" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Time course of hemosiderin production and clearance by human pulmonary macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1125726" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Occult pulmonary haemorrhage in leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/889174" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnostic lavage and occult pulmonary hemorrhage in thrombocytopenic immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605828" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diagnosis of pulmonary hemorrhage in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584173" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bronchoalveolar lavage in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037530" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The lipid-laden alveolar macrophage as a marker of aspiration in parenchymal lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1699708" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bronchoalveolar lavage in liquid paraffin pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721351" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bronchoalveolar lavage in the diagnosis of lipoid pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3671894" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnosis of a case of lipoid pneumonia by bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2295245" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Interstitial pulmonary disease induced by occupational exposure to paraffin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2117104" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bronchoalveolar lavage in the diagnosis of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327663" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12358356" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Primary pulmonary lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443993" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bronchoalveolar lavage fluid analysis provides diagnostic information on pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162113" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252115" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
